Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate Cancer
Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.
Diagnosis & Disease Information
PHS290 May Help Predict Lifetime Risk of Metastatic or Fatal Prostate Cancer
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.
First Predictive Biomarker for ADT Use in Prostate Cancer Validated
Investigators developed a multimodal deep learning architecture to learn from both clinicopathologic and digital imaging histopathology data and identify different outcomes by treatment type.
Risk of MACE Similar With Degarelix and Leuprolide in Prostate Cancer
The risk of death from any cause was higher with degarelix.
Study Reveals Causes of Premature Death in Testicular Cancer Survivors
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
Two Doses of COVID-19 Vaccine Appear Necessary to Protect Cancer Patients on Active Treatment
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
Active Surveillance Appropriate for Favorable Intermediate-Risk PCa
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
Screening for Frailty May Improve Outcomes for Older Patients With Genitourinary Malignancies
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Use of Palliative Care in Managing Genitourinary Malignancies May Vary Across the United States
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...